THERAPEUTICS
Delivering transformative medicines for most intractable diseases
- 01 SPECIALIZATION
Advancing an innovative pipeline with AI
Leveraging full tech
stack
End-to-end platform to maximize the likelihood of success
Matching modality
with biology
Rationally designed therapeutic modality to address disease biology
Best-in-class
differentiation
Differentiated drug properties to transform treatment landscape
Oncology
Immunology & Inflammation
Cardiometabolic
Neuroscience
- 02 PIPELINE HIGHLIGHT
Rapidly advancing a pipeline of preclinical antibody candidates against emerging targets.
Example 1: Tumor-targeting anti-FGFR2b ADC
Diseases
HER2-negative gastric and gastroesophageal junction (GEJ) cancer
Biology
FGFR2b overexpression is prevalent in ~ 30% advanced G/GEJ patients, making it an emerging target for targeted therapies such as ADC and T-cell engager.
Challenge
Antagonizing FGFR2b could lead to on-target ocular toxicity, which may be exacerbated by cytotoxic ADC payloads.
Product differentiation
Tumor microenvironment targeting with reduced off-tumor on-target toxicity
Technologies
-
• XtalFold®
• Multi-parametric engineering
Diseases
Inflammatory bowel diseases (IBD)
Biology
TL1A inhibition is a validated mechanism that may show synergies with IL-23 blockade for treating IBD.
Challenge
High immunogenicity risk; frequent dosing regimen
Product differentiation
Novel MoA; reduced immunogenicity; high potency; half-life extended
Technologies
-
• Xpotlight™ epitope-focusing antigen design
• Trilux™ 3-in-1 antibody discovery
• Multi-parametric engineering
Example 2: TL1A × IL-23 bispecific antibody
03 PARTNERING
Innovate together to build transformative medicines.
By leveraging our AI-powered platform, we are rapidly bringing the next wave of advanced biologics toward the clinic. We explore strategic pipeline partnership to achieve synergies in clinical development and commercialization.
